The MHLW has approved the use of Entyvio (SC) as maintenance therapy for the treatment of mod to sev. UC who have had an inadequate response to existing therapies
The approval was based on the P-III trials (MLN0002SC-3027 & 3030) evaluating the efficacy and safety of Entyvio SC as a maintenance therapy
Entyvio is a humanized mAb & was designed to specifically antagonize the α4β7 integrin, inhibiting the binding of α4β7 integrin to intestinal MAdCAM-1. The therapy was currently approved as an IV formulation for UC and the maintenance of mod. to sev. UC & CD and as SC formulation for the maintenance treatment of UC
Ref: Takeda | Image: Takeda
Related News:- Takeda’s Takhzyro (lanadelumab-flyo) Receives the US FDA’s sBLA Approval to Prevent Hereditary Angioedema Attacks in Children Aged ≥2 Years
